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Subintimal angioplasty: Our experience in the
treatment of 506 infrainguinal arterial occlusions
Eric C. Scott, MD, Andre Biuckians, MD, MPH, Ryan E. Light, MS, Jessica Burgess, BS,
George H. Meier III, MD, and Jean M. Panneton, MD, Norfolk, Va
Objective: The treatment of patients with chronic arterial occlusions involving the superficial femoral artery has changed
significantly with the incorporation of subintimal angioplasty (SIA) into vascular surgery practice. To more clearly define
technical feasibility, patency, and clinical outcomes of SIA, we reviewed our cumulative experience.
Methods: A retrospective review of all patients who underwent SIA of arterial occlusions originating in the superficial
femoral artery was performed. Patient history, demographics, procedural details, and follow-up information were
collected and analyzed. Patency, limb salvage, sustained improvement in claudication, freedom from surgical bypass, and
survival were determined by Kaplan-Meier analysis.
Results: From December, 2002, through July, 2006, 506 infrainguinal SIA procedures were performed in 472 patients
with chronic arterial occlusion involving the superficial femoral artery. The mean age of patients treated was 69.4  11.9
years and the indication for intervention was critical limb ischemia in 63% of limbs (n  317) and disabling claudication
in 37% (n  189). Forty-seven percent of limbs (n  237) had isolated SFA occlusions, 40% (n  205) had
femoropopliteal occlusions, and 13% of limbs had occlusions beginning in the SFA and extending into the tibial arteries
(n  64). Technical success was achieved in 87% of procedures. Following successful SIA, the mean ankle-brachial index
increased by 54%, from 0.50  0.16 to 0.77  0.23 (P < .0001). Median follow-up was 12.4 months (0-48 months) and
30-day mortality was 0.8%. Primary patency at 12 and 36 months was 45% (SE 3.0%) and 25% (SE 3.6%) respectively.
Secondary patency was 76% (SE 2.6%) and 50% (SE 4.8%) at 12 and 36 months. Factors associated with reduced primary
patency included femorotibial occlusions (HR 1.57, CI 1.05-2.36) and the presence of critical limb ischemia (HR 1.39,
CI 1.02-1.89). Limb salvage in patients with critical limb ischemia was 75% (SE 5.9%) at 36 months. Freedom from
surgical bypass in patients with either critical limb ischemia or disabling claudication was 77% (SE 4.1%) at 36 months.
Conclusion: SIA is an effective percutaneous technique for the revascularization of patients with lower extremity chronic
arterial occlusions involving the superficial femoral artery. The procedure is successfully performed in all segments of the
lower extremity with minimal morbidity or mortality. Rates of limb salvage and improvement in claudication are similar
to those achieved by open surgical bypass, while modest reductions in limb salvage and primary patency are experienced
in limbs with femorotibial occlusions. ( J Vasc Surg 2008;48:878-84.)Subintimal angioplasty (SIA), a percutaneous method
of lower extremity revascularization devised for the treat-
ment of arterial occlusions, is increasingly being utilized in
the United States. Discovered and initially popularized in
the United Kingdom, SIA has been used effectively in the
treatment of patients with critical limb ischemia as well as
disabling claudication, reports of which are now present in
both American and European literature.1-8
The majority of these reports have provided short-term
and mid-term outcomes in patients undergoing SIA for
critical limb ischemia, while fewer reports of patients
treated for disabling claudication exist.5,8 Most studies
have included relatively small numbers of patients, resulting
in limited statistical power to determine the types of pa-
tients and lesions best treated with SIA. With this in mind,
we reviewed our collective experience using SIA as primary
From the Division of Vascular Surgery, Eastern Virginia Medical School.
Competition of interest: none.
Presented at the 2007 Vascular Annual Meeting, Baltimore, Md, Mar
21-24, 2007.
Reprint requests: Jean M. Panneton, MD, Division of Vascular Surgery,
Eastern Virignia Medical School, Sentara Heart Hospital, 600 Gresham
Drive, Suite 8620, Norfolk, VA 23507 (e-mail: pannetjm@evms.edu).
0741-5214/$34.00
Copyright © 2008 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2008.05.037
878therapy for patients with disabling claudication or critical
limb ischemia due to arterial occlusions originating in the
superficial femoral artery (SFA).
METHODS AND MATERIALS
A retrospective review of all patients who underwent
SIA from December 1, 2002 through July 31, 2006 was
performed. Early in our use of SIA, patients treated were
those with impending limb loss who were at prohibitive
operative risk. As examples of limb salvage became numer-
ous and the safety of SIA became apparent, the procedure
was incorporated into first-line therapy for patients with
extensive arterial occlusions who were facing open bypass if
not for SIA. The vast majority of patients treated in this
review were treated as part of a SIA-first approach to long
segment occlusions not amenable to transluminal balloon
angioplasty. SIA was not used in the treatment of patients
with acute arterial occlusion or in patients with stenoses
alone. Patients treated for isolated iliac, popliteal, or tibial
artery occlusions were excluded from the study population.
Patient demographics, clinic notes, non-invasive vascular
studies, angiographic findings, and procedural reports were
reviewed following approval by the Institutional Review
Board.
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SFA to those extending through the popliteal artery into
one or more tibial arteries. The vast majority of procedures
were performed in an angiographic suite while the remain-
ing procedures were performed in an operating room with
non-fixed fluoroscopy if deep sedation, general anesthesia,
or simultaneous open surgical procedures were required.
Retrograde contralateral common femoral arterial punc-
ture was the preferred means of angiographic access. Fol-
lowing angiography and identification of an infrainguinal
arterial occlusion, patients were systemically heparinized.
Lesions were typically approached by placement of a sheath
over the aortic bifurcation and in proximity to the occlu-
sion. A soft, angled, hydrophilic 0.035-inch guidewire in
combination with a 4 French angled hydrophilic catheter
(Glidecath, Terumo Medical Corporation, Somerset, New
Jersey) were most commonly used to perform the subinti-
mal dissection. The subintimal plane was entered by forma-
tion of a loop at the end of the guidewire and advancing it,
along with the catheter, across the occluded arterial seg-
ment. Indicators of subintimal dissection included charac-
teristic resistance to wire advancement, a broad helical path
taken by the wire during advancement, the guidewire loop
assuming the width of the native vessel, and a subtle release
of wire resistance with true lumen re-entry near the distal
extent of arterial occlusion. Occlusions crossed with the
straight tip of a soft guidewire were considered translumi-
nal recanalizations and excluded from this review. After
confirmation of catheter re-entry into the true lumen,
balloon angioplasty was used to dilate the subintimal chan-
nel. Balloons measuring 5-6 mm were typically used in the
SFA, 4-5 mm balloons were typically used in the popliteal
artery, and 2.5-3 mm balloons were selected for tibial
angioplasty. Inflations were held for 60-120 seconds.
Stents were selectively deployed within the channel to
further open segments of suboptimal angioplasty, defined
as residual stenosis 30%. This was most commonly re-
quired in regions of heavy calcification and at subintimal
entry and re-entry points. Technical success consisted of
the creation of a subintimal channel around the occlusion,
successful re-entry into the true lumen, and balloon angio-
plasty establishing forward flow through the new lumen.
Following the procedure, patients received clopidogrel
for a minimum of one month and aspirin indefinitely.
Clinical follow-up at one month, three months, and six to
twelve months following the procedure was routine and
included physical examination and measurement of ankle-
brachial indices. Duplex examination of the subintimal
channel and further follow-up were obtained at the discre-
tion of the surgeon. All additional endovascular procedures
(balloon angioplasty, stenting, redo SIA, mechanical throm-
bolysis) to maintain or restore patency of the subintimal
channel were recorded, as were all open surgical revisions,
bypasses, major amputations, and deaths that occurred
through December 31, 2006.
Patency of SIAwas definedby at least one of the following
criteria: flow through the vessel demonstrated by angiography
or duplex ultrasound, maintenance of an ankle-brachial index0.10 above the pre-procedure value,9 or maintenance of a
palpable pedal pulse that was absent prior to the procedure in
a patient asymptomatic following the procedure. All percuta-
neous reinterventions on the SIA were recorded for calcula-
tion of primary-assisted and secondary patency, as previously
defined.9 Any limbs requiring open revascularization during
the follow-up period were recorded and considered an end-
point of SIA patency. Symptomatic improvement in patients
with critical limb ischemia was defined as the resolution of rest
pain or healing of ulcers and gangrenous wounds following
debridement or minor amputation. Symptomatic improve-
ment in patients with claudication was defined as improve-
ment in walking distance, as determined through follow-up
visits. Continuous data is expressed as mean standard devi-
ation and compared using Student’s t-test. P  .05 was
considered statistically significant. Patency, limb salvage,
symptomatic improvement, freedom from surgical bypass,
and survival were determined using Kaplan-Meier survival
analysis and compared by log-rank testing. Multivariate anal-
ysis was performed using Cox proportional-hazards regres-
sion. Data is presented based upon technical successes of SIA
to facilitate comparability of results between studies at a time
when the rate of technical success remains variable10,11 and
alters outcome data when analyzed on an intention-to-treat
basis.
RESULTS
Subintimal angioplasty was performed in 506 limbs
(472 patients) for infrainguinal arterial occlusions originat-
ing in the SFA between December 1, 2002 and July 31,
2006. Each procedure was performed by one of 14 board-
certified vascular surgeons. The median number of proce-
dures performed per surgeon was 34 (range, 6 to 62).
Subintimal angioplasty was used more frequently as the
study period progressed. In 2003, the first full year of study,
33 procedures were performed, while in 2005, 191 proce-
dures were performed.
Patient demographics are presented in Table I. The
indication for intervention was critical limb ischemia in 63%
of limbs (n  317) and disabling claudication in the re-
maining 37% of limbs (n  189). Forty-seven percent of
limbs (n  237) had isolated SFA occlusions, 40% (n 
205) had femoropopliteal occlusions, and 13% of limbs
(n 64) had occlusions beginning in the SFA and extend-
ing into the tibial arteries. Lesion lengths were not consis-
tently recorded at the time of procedure, however, the vast
majority of lesions treated were either TransAtlantic Inter-
Society Consensus (TASC) C or D (TASC I classification).
Subintimal angioplasty was performed in each limb
when the arterial occlusion was not amenable to translumi-
nal revascularization. The procedure was technically suc-
cessful in 87% of attempts (n  439). Technical success,
based upon the extent of the occlusion treated, ranged
from 84% in isolated SFA occlusions to 89% in cases of
occlusion extending into the popliteal and tibial arteries
(P .45). Failure to re-enter the true lumen accounted for
73% (n 49) of the 67 unsuccessful cases. Failure to enter
the subintimal plane (n  6), inability to cross the lesion
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subintimal channel following angioplasty (n  6) ac-
counted for the remainder of unsuccessful attempts. In
these 67 patients, 27 underwent subsequent surgical bypass
procedures, 12 underwent primary major amputation, and
nine patients died without further intervention. The re-
maining 19 patients had no further intervention by our
surgeons.
Adjunctive procedures were utilized in the treatment of
5.3% of limbs (n  27). These included open common
femoral endarterectomy (n  16), open common femoral
artery exposure to facilitate SIA (n  2), femoral-femoral
bypass (n  1), laser atherectomy (n  2), and use of
endoluminal re-entry devices (n  6). Bare metal stents
were deployed in 20.3% (n  89) of successful SIA proce-
dures. In these procedures, a mean of 1.6 0.8 stents were
used with a mean total stent length of 99.1  71.3 mm.
Complications occurred in 5.5% of procedures (n  28),
and included 15 arterial perforations (3.0%), none of which
resulted in hemorrhage, four femoral artery pseudoaneu-
rysms (0.8%), four episodes of distal embolization (0.8%),
two arteriovenous fistulas (0.4%), one groin soft-tissue
infection (0.2%), one groin hematoma (0.2%), one retro-
peritoneal hematoma (0.2%), and one common femoral
artery intimal flap (0.2%). Only the common femoral artery
intimal flap required open surgical intervention for correc-
tion. The remaining complications were treated conserva-
tively (n  21) or by percutaneous means alone (n  6).
Femoral pseudoaneurysms were treated by duplex-directed
thrombin injection as appropriate and distal emboli were
recovered with aspiration catheters.
Themedian follow-up was 12.4months (range, 0 to 48
months). In limbs successfully treated with SIA, 308 limbs
(70%) had pre-procedural ankle-brachial indices (ABI)
Table I. Patient demographics and risk factors for
peripheral arterial disease
Variable n %
Patients 472
Limbs 506
Mean age, years 69.4  11.9
Range, years 37-99
Male 284 56.1
Indication
Critical limb ischemia 317 62.7
Rest pain 131 25.9
Ulceration 127 25.1
Gangrene 59 11.7
Claudication 189 37.3
Risk Factors
Hypertension 361 71.9
Coronary artery disease 276 54.5
Diabetes mellitus 247 48.8
Tobacco use 237 47.3
Hyperlipidemia 190 37.8
Previous infrainguinal bypass 113 22.4
End-stage renal disease 62 12.3measured. The remaining 30% of limbs (n  198) pre-sented with tissue loss and were taken directly for angiog-
raphy and intervention or had ABI that could not be
located. Forty-three percent of limbs (n  189) had ABI
measured up to one month before and up to one month
after the procedure. In these limbs with paired pre- and
post-SIAmeasurements, themean increase in ABI was 0.27
(54%), from 0.50  0.16 to 0.77  0.23 (P  .0001).
Primary patency was 45% (SE 3.0%), 30% (SE 3.3%), and
25% (SE 3.6%) at 12, 24, and 36 months, respectively
(Fig. 1). Primary-assisted patency was 61% (SE 3.0%), 42%
(SE 3.6%), and 38% (SE 3.9%) at these intervals, while
secondary patency was 76% (SE 2.6%), 57% (SE 3.7%), and
50% (SE 4.8%). Subsequent endovascular procedures were
required to maintain or restore patency in 122 limbs (28%).
When patency of SIA was further analyzed based upon
the distal extent of arterial occlusion, reductions in patency
were observed for each more distal segment of occlusion
(Fig. 2). At 36months, primary patency was 31% (SE 6.6%)
in 200 limbs with isolated SFA occlusion, 20% (SE 5.2%)
for 182 femoropopliteal occlusions, and 16% (SE 6.9%) for
57 limbs with femorotibial occlusions. Primary patency of
femorotibial SIA was significantly lower than for femoro-
popliteal (P  .05) or isolated femoral SIA (P  .005).
Secondary patency at 36 months was 54% (SE 8.5%) for
femoral SIA, 48% (SE 7.1%) for femoropopliteal SIA, and
43% (SE 11.2%) for limbs requiring femorotibial SIA (Fig.
2). These differences did not reach statistical significance
(P  .08).
Multiple factors that may affect primary patency were
examined by univariate analysis (Table II). The presence of
diabetes, female gender, critical limb ischemia, and tibial
vessel re-entry were each associated with reduction in pri-
Fig 1. Patency of subintimal angioplasty in 439 limbs with arte-
rial occlusion originating in the superficial femoral artery. At 36
months, primary patency was 25% (SE 3.6%), primary-assisted
patency was 38% (SE 3.9%), and secondary patency was 50%
(4.8%). Standard errors are 10% for all data points.mary patency. In multivariate analysis, however, only fem-
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(HR  1.39) were identified as significant factors associ-
ated with reduced primary patency (Table III). Kaplan-
Meier analysis confirmed superior patency in limbs treated
for claudication. Primary and secondary patency at three
years was 30% (SE 6.2) and 52% (SE 7.9%) respectively, in
limbs treated for claudication, but was reduced to 21% (SE
4.5%) and 47% (SE 6.0%) in limbs with critical limb isch-
emia (P  .003, primary patency; P  .02, secondary
patency). Stent use was not associated with improved pa-
tency (HR  0.96). Primary patency at three years in
patients requiring stent placement was 28% compared with
24% in those who did not (P  .59). Secondary patency at
three years was 45% in patients receiving stents and 51% in
Fig 2. Primary patency of subintimal angioplasty by extent of
occlusion. At 36 months, primary patency in limbs with isolated
superficial femoral artery (SFA) occlusion was 31% (SE 6.6%). In
limbs with femoropopliteal occlusion, primary patency was 20%
(SE 5.2%), and in limbs with femorotibial occlusion, primary
patency was 16% (SE 6.9). Primary patency in limbs with femo-
rotibial occlusion was significantly reduced in comparison to limbs
with isolated SFA occlusion (P  .005) or femorotibial occlusion
(P  .05). Standard errors are 10% for all data points.
Table II. Univariate analysis of factors potentially
associated with reduced primary patency of subintimal
angioplasty
Risk Factors HR 95% CI P
Tobacco use 0.92 0.68-1.22 .55
Hypertension 0.95 0.69-1.30 .72
Stent use 0.96 0.69-1.33 .79
Coronary artery disease 1.01 0.75-1.36 .94
Diabetes mellitus 1.33 1.01-1.82 .04
Female gender 1.35 1.02-1.85 .03
Critical limb ischemia 1.58 1.18-2.10 .002
Femorotibial occlusion 1.66 1.16-2.99 .01
HR, hazard ratio; CI, confidence interval.patients who did not (P  .47).Surgical bypass was performed in 49 of 439 limbs
(11.2%) at a mean of 8.5  8.2 months following SIA.
Sixty-three percent of bypasses (31 of 49) were performed
in critically ischemic limbs. By Kaplan-Meier analysis, free-
dom from surgical bypass was 77% (SE 4.1%) at three years.
There were no patients for whom SIA was believed to have
altered the level of surgical bypass.
Major amputation (above-knee or below-knee) was re-
quired in 31 of 439 limbs (7.1%) at a mean of 8.2  10.1
months. Limb salvage in 265 limbs treated for CLI was
achieved in 88% (SE 2.5%) of limbs at 12 months, 81% (SE
3.9%) of limbs at 24months, and75% (SE5.9%) of limbs at 36
months. Only one amputation was performed in a patient
who presented with disabling claudication. This occurred 35
months following femoropopliteal SIA in a patient who pro-
gressed to gangrene of the foot secondary to worsening tibial
vessel disease. Prior to amputation, a femorotibial bypass and
a popliteal-tibial bypass had been performed in the preceding
two years, each of which failed following progression of dis-
ease. Limb salvage was further analyzed by extent of occlusion
(Fig. 3). At 36 months, limb salvage was 88% (SE 4.1%) in
limbs with isolated SFA occlusions, 68% (SE 11.1%) in limbs
with femoropopliteal occlusions, and64% (SE11.0%) in limbs
with femorotibial occlusions. In comparison to isolated SFA
occlusions, limb salvage for femorotibial occlusionswas signif-
icantly reduced (P .02).
There were 174 limbs treated for disabling claudication
with SIA. Claudication was improved or eliminated in 96.8%
of limbs three months following the procedure. Sustained
improvement in walking distance was attained in 90% (SE
2.7%) of limbs at 12 months, 76% (SE 4.7%) of limbs at 24
months, and 67% (SE 7.5%) of limbs at 36 months. No
differences in outcomes were found between limbs with iso-
lated femoral versus femoropopliteal occlusions (P  .45).
The small number of femorotibial procedures for claudication
(n 8) precluded meaningful statistical comparison.
There were four deaths (0.8%) within 30 days of the
procedure, none of which were attributed to the vascular
intervention. A total of 64 patients (14%) died during the
study period, 56 of whom had critical limb ischemia. By
Kaplan-Meier analysis, three-year survival in patients with
disabling claudication was 84% (SE 6.8%) (Fig. 4). In
patients with critical limb ischemia, three-year survival was
Table III. Multivariate analysis of factors associated with
reduced primary patency of subintimal angioplasty
Risk Factors b SE HR 95% CI P
Femorotibial
occlusion
0.45 0.21 1.57 1.05-2.36 .03
Critical limb ischemia 0.33 0.16 1.39 1.02-1.89 .04
Female gender 0.27 0.15 1.31 0.98-1.75 .07
Diabetes mellitus 0.25 0.15 1.28 0.95-1.73 .11
b, beta; SE, standard error; HR, hazard ratio; CI, confidence interval.55% (SE 7.8%).
JOURNAL OF VASCULAR SURGERY
October 2008882 Scott et alDISCUSSION
The role of SIA in the care of patients with peripheral
arterial disease is gradually emerging as numerous centers
now report their experience with the technique.12-17 What
began as a salvage technique for patients facing amputation
without surgical options has now become a valuable tool in
the endovascular arsenal of surgeons treating increasingly
Fig 3. Limb salvage by extent of arterial occlusion. At 36months,
limb salvage was 88% (SE 4.1%), 68% (SE 11.1%), and 64% (SE
11.0%) for limbs with isolated SFA, femoropopliteal, and femo-
rotibial occlusion, respectively. In comparison to limbs with iso-
lated SFA occlusion, limb salvage in extremities with femorotibial
occlusion was significantly reduced (P  .02). Fine dotted line
denotes SE  10%.
Fig 4. Survival in 472 patients with disabling claudication or
critical limb ischemia (CLI) secondary to infrainguinal arterial
occlusion involving the superficial femoral artery. At three years,
survival was 84% (SE 6.8%) in patients with claudication and 55%
(SE 7.8%) in those with CLI (P  .0001). Standard errors are
10% for all data points.complex arterial occlusions.In this report, the largest review of SIA published to
date, we provide new data on the patency and clinical
outcomes of patients treated with SIA for arterial occlu-
sions originating in the SFA. In all patients, primary pa-
tency of SIA was 45% at one year and 25% at three years.
During this period, 28% of patients required percutaneous
reintervention to maintain or restore patency of the subin-
timal channel. This resulted in secondary patency of 76% at
one year and 50% at three years. These results are compa-
rable to prior reports of SIA,2,6,8,14,17,18 and are also com-
parable to published results of prosthetic bypass patency at
five years ranging from 39% to 77% for above-knee bypass,
to 25% for tibial bypass.19-22 Secondary patency of SIA
appears to be inferior to that of historical saphenous vein
bypass results, which have been reported in many earlier
studies to be between 74% and 85%.19,21,23-25 However,
our results approach vein bypass outcomes recently re-
ported in the PREVENT III trial that evaluated one-year
outcomes in 1404 similarly co-morbid patients with critical
limb ischemia.26 In this study, conducted between 2001
and 2003, primary, primary-assisted, and secondary pa-
tency at one year were 61%, 77%, and 80%. These results are
not surprising, as many patients with TASC Class A, B, and
even C lesions – lesions once treated with surgical bypass –
are now treated percutaneously per TASC and TASC II
guidelines.27,28 The remaining population of patients,
largely those with TASC C and D lesions, are by definition,
those with the most extensive disease.
Despite the modest overall patency of SIA, clinical
outcomes in patients with either disabling claudication or
critical limb ischemia were clearly better than patency data
would predict, and are similar to those achieved by surgical
bypass.26,29 In our patients, limb salvage in patients with
CLI was 75% at three years and 67% of patients with
disabling claudication reported improvement or resolution
of symptoms at three years. Overall, only 23% of patients
treated with SIA required surgical bypass during the study
period. There are several possible explanations for the
modest discrepancy between patency data and clinical out-
comes. First, patency was determined by strict objective
assessment only. Long-term follow-up evaluations of pa-
tients doing well and “clinically” patent but without objec-
tive evidence of such were not considered in Kaplan-Meier
calculations of patency. As a result, the actual patency may
have been compromised by the lack of uniform ABI and
arterial duplex assessment in the post-procedure period.
Comparison of “clinical patency” with limb salvage may
have yielded more similar results. Second, successful SIA
enabled wound healing and healing of minor lower extrem-
ity amputations, after which loss of SIA patency may not
have lead to recurrence of symptoms. Third, SIA may have
provided time for patients to develop additional collateral
circulation, reducing or eliminating recurrence of symp-
toms in some patients whose SIA later failed. Finally, sur-
vival of patients with critical limb ischemia in this series was
only 55% at three years. Due to the impact of multiple
medical co-morbidities present within this portion of our
study population, many who experience SIA failure do not
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cal bypass or amputation.
There are several unique findings of this study. The first
is that SFA occlusions extending into the popliteal or tibial
arteries do not negatively impact technical success. When
analyzed by extent of occlusion, there were no differences
in rates of technical success. In addition, there was limited
use of re-entry devices during the study period, as they have
only recently become available. Increased use of such de-
vices will likely improve rates of technical success for SIA
based upon early reported experience with these devices.30
The second unique finding is that the primary patency
of SIA and limb salvage is impacted by the distal extent of
arterial occlusion. Over half of the limbs treated in this
study presented with occlusions originating in the SFA that
continued into either the popliteal or tibial arteries. Pa-
tients treated with SIA for femorotibial occlusions experi-
enced significant reductions in primary patency. This dif-
ference was less pronounced in examination of secondary
patency, but the trend persisted. Limb salvage at three years
was likewise reduced in patients with femorotibial occlu-
sions. Similarly, Lazaris et al have reported on 46 patients
with critical limb ischemia and various levels of infraingui-
nal disease treated with SIA and found length of occlusion
to be an independent predictor of reduced patency.31
However, the individual arterial segments involved were
varied among these patients and is a potentially confound-
ing factor when calculating the importance of length.
The third important finding is that selective stenting of
portions of the subintimal channel not well expanded by
angioplasty alone results in equivalent patency to those
patients who receive successful SIA alone. There were no
significant differences in primary or secondary patency be-
tween patients who required stent placement and those
who did not. Treiman et al14 reported SIA results utilizing
a primary stent placement approach in 29 patients with
critical limb ischemia. While primary patency was 85% at
one year, patency fell to 18% at three years and 9% at four
years. Although recent reports of intraluminal SFA angio-
plasty have demonstrated an early benefit to primary stent-
ing,32,33 we do not believe these results can be readily
applied to subintimal revascularization. Instead, we believe
that selective stent placement for suboptimal angioplasty is
a reasonable approach and likely improves patency in those
patients requiring it, resulting in nearly equivalent out-
comes at three years.
As SIA provided similar limb salvage in our patients
with critical limb ischemia and durable relief from claudi-
cation, with less morbidity and mortality than reported for
open bypass, the role of SIA in the care of patients with
peripheral vascular disease is now more clearly defined
within the authors’ practice. A SIA-first approach has been
adopted for nearly all patients presenting with symptomatic
occlusions involving the SFA. Patients almost unanimously
prefer this approach when percutaneous and open surgical
options are discussed prior to angiography, and as SIA does
not preclude later surgical bypass,6,8,34 this option is pre-
served for the minority of patients who might later requireit. More importantly, SIA offers a less morbid means of
revascularization to many patients, who by virtue of their
medical co-morbidities are either poor surgical candidates
or are at prohibitive surgical risk.
There are several limitations to the present study. First,
it is a retrospective review of a large vascular surgery prac-
tice conducted at multiples sites. The use of periprocedural
and follow-up non-invasive testing was less frequent than
would be expected in a prospective trial. Second, the review
consists of a heterogeneous population of infrainguinal
arterial occlusions. While it would have been more concise
to study occlusions limited to the SFA, we found that over
half of our patients with occlusions originating in the SFA
had extension of the occlusion into either the popliteal or
tibial artery. To maintain some uniformity, however, iso-
lated popliteal and tibial artery occlusions were excluded,
and thus our results should not be construed as those for
popliteal or tibial artery SIA. Finally, clinical endpoints
including relief from claudication and freedom from surgi-
cal bypass were used to provide additional insight into
patient outcomes, yet each is susceptible to surgeon bias.
CONCLUSION
Subintimal angioplasty is a valuable tool in the arma-
mentarium of endovascular surgeons treating lower ex-
tremity arterial occlusions originating in the SFA. Limb
salvage and improvement in claudication are excellent at
three years, sparing most patients the need for surgical
bypass during this time. As with surgical bypass, minor
reductions in patency and limb salvage are seen with exten-
sion of intervention into the tibial arteries. However, the
percutaneous nature of SIA makes it an appealing first-line
therapy for many patients with SFA occlusion, and an
especially valuable technique for the revascularization of
patients who are either hesitant to undergo bypass surgery
or are at high surgical risk.
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